Management fee of $0.05 - that's 20% of the share value at the moment!4 Apr 2023 15:44
Biodexa Pharmaceuticals plc formerly known as Midatech Pharma plc has announced its intention to cancel its listing of ordinary shares from trading on AIM. This is expected to become effective on 26th April 2023.
As the company's American Depository Shares (ADSs) will continue to be traded on NASDAQ, if you choose not to sell your ordinary shares by 17th April 2023, we will arrange for them to be converted to ADSs. The company have stated that any such conversion will not be subject to Stamp Duty or SDRT at 1.5%, neither will it be subject to the usual conversion fee of up to USD0.05 per ADS. Each ADS is equivalent to 5 ordinary shares and as such if your holding is not divisible by 5 you may wish to sell any residual stock before 17th April 2023. The process of converting Ordinary shares to ADSs may take a short period of time; you will not be able to sell the ordinary shares or ADSs during this period. Bank of New York currently charge an annual ADS management fee of USD0.05 per ADS. Any fees charged by Bank of New York for holding the ADSs in future will be passed on to you accordingly. Full details on the ADSs can be found on the website at the following link: